936 related articles for article (PubMed ID: 29436828)
21. Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex.
Soldevila-Barreda JJ; Azmanova M; Pitto-Barry A; Cooper PA; Shnyder SD; Barry NPE
ChemMedChem; 2020 Jun; 15(11):982-987. PubMed ID: 32237195
[TBL] [Abstract][Full Text] [Related]
22. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
23. Dinuclear [{(p-cym)RuCl}2(μ-phpy)](PF6)2 and heterodinuclear [(ppy)2Ir(μ-phpy)Ru(p-cym)Cl](PF6)2 complexes: synthesis, structure and anticancer activity.
Tripathy SK; De U; Dehury N; Pal S; Kim HS; Patra S
Dalton Trans; 2014 Oct; 43(39):14546-9. PubMed ID: 25160655
[TBL] [Abstract][Full Text] [Related]
24. Differences in Stability, Cytotoxicity, and Mechanism of Action of Ru(II) and Pt(II) Complexes of a Bidentate N,O Donor Ligand.
Maji M; Acharya S; Maji S; Purkait K; Gupta A; Mukherjee A
Inorg Chem; 2020 Jul; 59(14):10262-10274. PubMed ID: 32585099
[TBL] [Abstract][Full Text] [Related]
25. Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives.
Lee SY; Kim CY; Nam TG
Drug Des Devel Ther; 2020; 14():5375-5392. PubMed ID: 33299303
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.
Sangeetha S; Murali M
Inorg Chem; 2022 Feb; 61(6):2864-2882. PubMed ID: 35099196
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin.
Bakalova AG; Buyukliev RT; Nikolova RP; Shivachev BL; Mihaylova RA; Konstantinov SM
Anticancer Agents Med Chem; 2019; 19(10):1243-1252. PubMed ID: 30767754
[TBL] [Abstract][Full Text] [Related]
28. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
[TBL] [Abstract][Full Text] [Related]
29. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
30. Bifunctional ruthenium(ii) polypyridyl complexes of curcumin as potential anticancer agents.
Li S; Xu G; Zhu Y; Zhao J; Gou S
Dalton Trans; 2020 Jul; 49(27):9454-9463. PubMed ID: 32598409
[TBL] [Abstract][Full Text] [Related]
31. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
32. Square planar Au(III), Pt(II) and Cu(II) complexes with quinoline-substituted 2,2':6',2″-terpyridine ligands: From in vitro to in vivo biological properties.
Choroba K; Machura B; Szlapa-Kula A; Malecki JG; Raposo L; Roma-Rodrigues C; Cordeiro S; Baptista PV; Fernandes AR
Eur J Med Chem; 2021 Jun; 218():113404. PubMed ID: 33823390
[TBL] [Abstract][Full Text] [Related]
33. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and anti-cancer activity of bis-amino-phosphine ligand and its ruthenium(II) complexes.
Engelbrecht Z; Roberts KE; Hussan A; Amenuvor G; Cronjé MJ; Darkwa J; Makhubela BCE; Sitole L
Bioorg Med Chem Lett; 2020 Oct; 30(20):127492. PubMed ID: 32791194
[TBL] [Abstract][Full Text] [Related]
35. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
36. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S
J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123
[TBL] [Abstract][Full Text] [Related]
37. Cancer-Specific, Intracellular, Reductive Activation of Anticancer Pt
Reshetnikov V; Daum S; Mokhir A
Chemistry; 2017 Apr; 23(24):5678-5681. PubMed ID: 28319647
[TBL] [Abstract][Full Text] [Related]
38. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of series of diazine-bridged dinuclear platinum(II) complexes through in vitro toxicity and molecular modeling: correlation between structure and activity of Pt(II) complexes.
Senerovic L; Zivkovic MD; Veselinovic A; Pavic A; Djuran MI; Rajkovic S; Nikodinovic-Runic J
J Med Chem; 2015 Feb; 58(3):1442-51. PubMed ID: 25551180
[TBL] [Abstract][Full Text] [Related]
40. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
